Rheumatology research report, Vol. 11, issue 3, Fall 2014

In this edition there are three new studies on arthritis and periodic fever syndromes, information about a new logo contest and about ongoing studies that are open for recruitment. Results from a recent study that looked at data from the ReACCh-Out database are shared.Medicine, Faculty ofRheumatology, Division ofMedicine, Department ofUnreviewedUndergraduateOthe

Rheumatology research report, Vol. 9, issue 2, Fall 2012

This report covers a new study on arthritis as well as answers some questions about participating in research studies.Medicine, Faculty ofRheumatology, Division ofMedicine, Department ofUnreviewedOthe

Rheumatology research report, Vol. 12, issue 1, Spring 2015

The Spring 2015 edition decribes two new studies on uveitis and arthritis. It also provides an update on the LEAP exercise intervention project and shares results from the Pediatric Vasculitis Initiative.Medicine, Faculty ofPediatrics, Department ofRheumatology, Division ofMedicine, Department ofUnreviewedOthe

Rheumatology research report, Vol. 10, issue 1, Winter 2013

This edition of the newsletter tells about the importance of research registries, introduces some LEAP ambassadors, and provides an update on patient and parent focus groups held a few months ago.Medicine, Faculty ofRheumatology, Division ofMedicine, Department ofUnreviewedOthe

Comparing presenting clinical features of 48 children with microscopic polyangiitis (MPA) against 183 having granulomatosis with polyangiitis (GPA)

Objectives: To uniquely classify children with MPA, describe their demographics, presenting features, initial treatments, and compare with GPA patients. Methods: The European Medicines Agency (EMA) classification algorithm, applied by computation to categorical data of patients recruited to A Registry for Childhood Vasculitis, censored to November 2015, uniquely distinguished MPA from GPA patients who were classified with adult and pediatric-specific criteria. Descriptive statistics were used for comparisons. Results: 231 (64% female) of 440 patients fulfilled classification criteria for either MPA (n=48) or GPA (n=183); respectively median time-to-diagnosis was 1.6 and 2.1 months, range to 39 and 73 months. Comparing MPA versus GPA patients respectively they were significantly younger (median 11 versus 14 years); constitutional features were equally common; pulmonary manifestations (44% versus 74%) were less frequent and less severe (hemorrhage, oxygen-requiring, pulmonary failure); renal features (76% versus 83%) were similarly frequent but tended towards greater severity (nephrotic-range proteinuria, dialysis-requirement, end-stage disease). Airway/eye involvement was absent among MPA patients as these GPA-defining features preclude an MPA diagnosis within the EMA algorithm. MPA and GPA patients respectively received combination therapy with corticosteroids plus cyclophosphamide (69% and 78%) plus plasmapheresis (19% and 22%). Other treatments in decreasing frequencies from 13% to 3% were rituximab, methotrexate, azathioprine, and mycophenolate mofetil. Conclusion: Younger onset age, and perhaps both gastrointestinal manifestations and worse kidney disease seem to characterize children with MPA versus GPA. Delay in diagnosis suggests suboptimal recognition. Compared to adults, initial treatments are comparable, but the complete reversal of female to male prevalence ratios is provocative.Medicine, Faculty ofNon UBCMedicine, Department ofRheumatology, Division ofPediatrics, Department ofReviewedFacultyOthe